Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21561643 | 0.74 | ALDH1A1 (0.34) | NPC1ALDH1A1NPSR1HSD17B10 | |
| SCHEMBL21561662 | 0.73 | PDK1 (0.48) | POLBNPC1ALDH1A1NPSR1HSD17B10 | |
| SCHEMBL21561651 | 0.73 | PDK1 (0.48) | POLBNPC1ALDH1A1NPSR1HSD17B10 | |
| SCHEMBL21561649 | 0.69 | FKBP1A (0.35) | NPC1ALDH1A1 | |
| SCHEMBL18630077 | 0.69 | — | — | |
| SCHEMBL14191772 | 0.69 | — | — | |
| SCHEMBL20204848 | 0.65 | SMN1; SMN2 (0.32) | — | |
| SCHEMBL9700171 | 0.59 | SMN1; SMN2 (0.46) | POLBNPC1ALDH1A1NPSR1HSD17B10 | |
| SCHEMBL11107659 | 0.58 | MAPKAPK2 (0.34) | — | |
| SCHEMBL10066991 | 0.56 | ALDH1A1 (0.38) | NPC1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10969394-B2 | Reagents and methods for analysis of proteins and metabolites targeted by covalent probes | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-04-06 | — | — | US | disclosed |
| US-20190346454-A1 | Reagents and Methods for Analysis of Proteins and Metabolites Targeted by Covalent Probes | DANA-FARBER CANCER INSTITUTE, INC. | 2019-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10969394-B2 | Reagents and methods for analysis of proteins and metabolites targeted by covalent probes | PTMS, SRMS, HSP90B1 | POLB 3536/4885NPC1 2787/4885ALDH1A1 1092/4885 |
| US-20190346454-A1 | Reagents and Methods for Analysis of Proteins and Metabolites Targeted by Covalent Probes | PTMS, SRMS, HSP90B1 | POLB 3536/4885NPC1 2787/4885ALDH1A1 1092/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.